Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.
Larrosa-Garcia, M, Baer, MR
Daver, N, Schlenk, RF, Russell, NH, Levis, MJ
Staudt, D, Murray, HC, McLachlan, T, Alvaro, F, Enjeti, AK, Verrills, NM, Dun, MD
© 2021 Reactome